Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:39 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MPS Pharmaa Ltd operates within the pharmaceuticals sector, focusing on developing and marketing pharmaceutical products. The company’s sales have recorded a concerning trend, with reported revenues of ₹0.00 for the last five quarters, including the latest quarter ending September 2023. This stagnation in sales is consistent with the reported figures from previous periods, where the total sales for the fiscal year ending March 2023 also stood at ₹0.00. Historically, the company experienced a peak in sales of ₹30.27 Cr in March 2014, which has since declined significantly, indicating a troubling trajectory. The absence of revenue generation raises concerns regarding the company’s operational viability and market competitiveness. Furthermore, MPS Pharmaa has not reported any substantial other income, which further exacerbates the challenges faced by the company in sustaining itself financially without a robust revenue stream.
Profitability and Efficiency Metrics
The profitability metrics of MPS Pharmaa Ltd showcase a series of losses, with a net profit of -₹0.89 Cr reported for the latest financial year. The company has consistently incurred losses, with a net profit of -₹1.05 Cr in March 2023, and a declining trend in profitability over the years. The operating profit margin (OPM) has remained negative, reflecting operational inefficiencies. The interest coverage ratio (ICR) is extremely low at -1438.08x, indicating that the company earns significantly less than its interest obligations, raising alarms about its ability to service debt. Furthermore, the return on equity (ROE) stands at a staggering 59.0%, but this figure is misleading as it is derived from negative earnings, suggesting that shareholder value is not being created. Overall, the company’s operational inefficiencies and profit losses signal a critical need for restructuring or strategic interventions to restore profitability.
Balance Sheet Strength and Financial Ratios
MPS Pharmaa Ltd’s balance sheet reveals significant challenges, particularly with a negative reserve of ₹-18.47 Cr, highlighting accumulated losses that have eroded the company’s equity. The total borrowings have increased to ₹7.51 Cr, which, juxtaposed with an equity capital of ₹19.11 Cr, results in a high debt-equity ratio of 6.90, indicating substantial leverage. This high level of debt raises concerns over financial stability, especially given the company’s inability to generate profits. Additionally, the current ratio of 0.25 and the quick ratio of 0.19 suggest liquidity issues, as the company has insufficient short-term assets to cover its liabilities. The price-to-book value (P/BV) ratio stands at 5.63x, indicating that the market values the company’s equity significantly higher than its book value, which may reflect speculative investor sentiment rather than fundamental strength.
Shareholding Pattern and Investor Confidence
The shareholding pattern of MPS Pharmaa Ltd indicates a stable yet concerning structure, with promoters holding 35.89% of the company. The public holds a significant 63.52%, while domestic institutional investors (DIIs) have a minimal stake of 0.58%. Over the past year, the number of shareholders has slightly declined from 4,512 in December 2022 to 4,433 in September 2025, indicating a potential waning interest from investors. The lack of foreign institutional investment (FIIs) may suggest a lack of confidence in the company’s future prospects. The consistent promoter holding suggests some level of commitment from the founders, but the overall lack of institutional backing and declining shareholder numbers could indicate a lack of confidence in the company’s ability to turn around its fortunes, especially amid ongoing operational losses.
Outlook, Risks, and Final Insight
Looking ahead, MPS Pharmaa Ltd faces significant risks, primarily stemming from its inability to generate revenue and maintain profitability. The company’s high leverage and liquidity issues pose additional threats to its financial health. If it fails to address its operational inefficiencies and generate consistent revenue, it risks further financial deterioration. However, should MPS Pharmaa successfully implement strategic changes, such as exploring new revenue streams or optimizing operational efficiency, there may be potential for recovery. The pharmaceutical sector remains competitive, and MPS Pharmaa could leverage its existing capabilities to regain market share. In conclusion, the company’s current state is precarious, requiring urgent attention to stabilize its financial metrics and restore investor confidence, or it may face dire consequences in the near future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 102 | 184/84.3 | 28.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,684 Cr. | 338 | 479/192 | 77.1 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.4 Cr. | 42.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.8 Cr. | 54.5 | 54.5/17.0 | 190 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.98 Cr | 1,117.31 | 54.75 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.24 | 0.23 | 0.31 | 0.19 | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 | 0.19 |
| Operating Profit | -0.24 | -0.23 | -0.31 | -0.19 | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 | -0.19 |
| OPM % | |||||||||||||
| Other Income | 0.00 | 0.00 | 0.02 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.28 | -0.27 | -0.33 | -0.20 | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 | -0.23 |
| Tax % | 0.00% | 0.00% | -3.03% | -5.00% | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% | -4.35% |
| Net Profit | -0.27 | -0.26 | -0.32 | -0.19 | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 | -0.22 |
| EPS in Rs | -0.14 | -0.14 | -0.17 | -0.10 | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 | -0.12 |
Last Updated: January 6, 2026, 8:06 pm
Below is a detailed analysis of the quarterly data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.19 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.19 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.19 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.23 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.23 Cr..
- For Tax %, as of Sep 2025, the value is -4.35%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -4.35%.
- For Net Profit, as of Sep 2025, the value is -0.22 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.22 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.12. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded -0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.27 | 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 27.43 | 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.75 |
| Operating Profit | 2.84 | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.75 |
| OPM % | 9.38% | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| Other Income | 0.01 | 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 |
| Interest | 1.20 | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.68 | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | 0.97 | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -0.87 |
| Tax % | 50.52% | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | |
| Net Profit | 0.46 | -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -0.89 |
| EPS in Rs | 0.31 | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -247.83% | -75.00% | -521.01% | 88.23% | -43.68% | 6.40% | -277.78% | 96.83% | -650.00% | 20.95% | -8.43% |
| Change in YoY Net Profit Growth (%) | 0.00% | 172.83% | -446.01% | 609.24% | -131.91% | 50.08% | -284.18% | 374.61% | -746.83% | 670.95% | -29.39% |
MPS Pharmaa Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 5% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | -24% |
| 5 Years: | -44% |
| 3 Years: | -39% |
| Last Year: | -59% |
Last Updated: September 5, 2025, 3:51 pm
Balance Sheet
Last Updated: December 4, 2025, 3:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 5.05 | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -18.47 |
| Borrowings | 8.22 | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.51 |
| Other Liabilities | 6.52 | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.84 |
| Total Liabilities | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
| Fixed Assets | 15.18 | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.74 |
| CWIP | 0.00 | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.65 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 18.72 | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 2.06 |
| Total Assets | 34.82 | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.99 |
Below is a detailed analysis of the balance sheet data for MPS Pharmaa Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.11 Cr..
- For Reserves, as of Sep 2025, the value is -18.47 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -18.03 Cr. (Mar 2025) to -18.47 Cr., marking a decline of 0.44 Cr..
- For Borrowings, as of Sep 2025, the value is 7.51 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.46 Cr. (Mar 2025) to 7.51 Cr., marking an increase of 0.05 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.80 Cr. (Mar 2025) to 0.84 Cr., marking an increase of 0.04 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.99 Cr.. The value appears to be improving (decreasing). It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.74 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Mar 2025) to 3.74 Cr., marking a decrease of 0.09 Cr..
- For CWIP, as of Sep 2025, the value is 2.65 Cr.. The value appears to be declining and may need further review. It has decreased from 2.91 Cr. (Mar 2025) to 2.65 Cr., marking a decrease of 0.26 Cr..
- For Investments, as of Sep 2025, the value is 0.54 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.54 Cr..
- For Other Assets, as of Sep 2025, the value is 2.06 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.06 Cr..
- For Total Assets, as of Sep 2025, the value is 8.99 Cr.. The value appears to be declining and may need further review. It has decreased from 9.34 Cr. (Mar 2025) to 8.99 Cr., marking a decrease of 0.35 Cr..
However, the Borrowings (7.51 Cr.) are higher than the Reserves (-18.47 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.38 | -6.97 | -7.14 | -9.78 | -3.43 | -3.24 | -3.20 | -9.82 | -6.49 | -7.72 | -8.07 | -8.23 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104.30 | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | |||||
| Inventory Days | 94.81 | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | ||||
| Days Payable | 62.46 | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | ||||
| Cash Conversion Cycle | 136.65 | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | |||||
| Working Capital Days | 99.72 | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | |||||
| ROCE % | 8.18% | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Diluted EPS (Rs.) | -0.47 | -0.43 | -0.55 | -0.07 | -2.31 |
| Cash EPS (Rs.) | -0.39 | -0.35 | -0.47 | 0.19 | -2.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 0.56 | 1.03 | 1.46 | 2.00 | 2.07 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| PBDIT / Share (Rs.) | -0.37 | -0.36 | -0.48 | -0.21 | -2.06 |
| PBIT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| PBT / Share (Rs.) | -0.45 | -0.44 | -0.56 | -0.48 | -2.35 |
| Net Profit / Share (Rs.) | -0.46 | -0.43 | -0.54 | -0.07 | -2.31 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -1290.32 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -2876.76 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -2880.22 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -437.31 | 0.00 |
| Return on Networth / Equity (%) | -83.08 | -42.21 | -37.63 | -3.70 | -111.78 |
| Return on Capital Employeed (%) | -68.24 | -38.85 | -35.47 | -22.83 | -96.84 |
| Return On Assets (%) | -9.62 | -8.36 | -10.31 | -1.39 | -39.07 |
| Total Debt / Equity (X) | 6.90 | 3.69 | 2.42 | 1.52 | 0.48 |
| Current Ratio (X) | 0.25 | 0.27 | 0.29 | 0.33 | 0.32 |
| Quick Ratio (X) | 0.19 | 0.20 | 0.22 | 0.24 | 0.24 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.08 | 0.03 | 0.00 |
| Interest Coverage Ratio (X) | -1438.08 | -563.32 | -1722.46 | -373.22 | -7579.04 |
| Interest Coverage Ratio (Post Tax) (X) | -1800.93 | -662.72 | -1955.76 | -125.49 | -8500.46 |
| Enterprise Value (Cr.) | 13.53 | 13.40 | 10.77 | 8.45 | 3.35 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 261.01 | 0.00 |
| EV / EBITDA (X) | -18.88 | -19.00 | -11.65 | -20.23 | -0.85 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 82.05 | 0.00 |
| Price / BV (X) | 5.63 | 3.12 | 1.44 | 0.69 | 0.36 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 86.88 | 0.00 |
| EarningsYield | -0.14 | -0.13 | -0.26 | -0.05 | -3.08 |
After reviewing the key financial ratios for MPS Pharmaa Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.43 (Mar 24) to -0.47, marking a decrease of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.39. This value is below the healthy minimum of 3. It has decreased from -0.35 (Mar 24) to -0.39, marking a decrease of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 0.56. It has decreased from 1.03 (Mar 24) to 0.56, marking a decrease of 0.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 2. It has decreased from -0.36 (Mar 24) to -0.37, marking a decrease of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.45. This value is below the healthy minimum of 0. It has decreased from -0.44 (Mar 24) to -0.45, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 2. It has decreased from -0.43 (Mar 24) to -0.46, marking a decrease of 0.03.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -83.08. This value is below the healthy minimum of 15. It has decreased from -42.21 (Mar 24) to -83.08, marking a decrease of 40.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is -68.24. This value is below the healthy minimum of 10. It has decreased from -38.85 (Mar 24) to -68.24, marking a decrease of 29.39.
- For Return On Assets (%), as of Mar 25, the value is -9.62. This value is below the healthy minimum of 5. It has decreased from -8.36 (Mar 24) to -9.62, marking a decrease of 1.26.
- For Total Debt / Equity (X), as of Mar 25, the value is 6.90. This value exceeds the healthy maximum of 1. It has increased from 3.69 (Mar 24) to 6.90, marking an increase of 3.21.
- For Current Ratio (X), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 1.5. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
- For Quick Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.20 (Mar 24) to 0.19, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1,438.08. This value is below the healthy minimum of 3. It has decreased from -563.32 (Mar 24) to -1,438.08, marking a decrease of 874.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1,800.93. This value is below the healthy minimum of 3. It has decreased from -662.72 (Mar 24) to -1,800.93, marking a decrease of 1,138.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.53. It has increased from 13.40 (Mar 24) to 13.53, marking an increase of 0.13.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -18.88. This value is below the healthy minimum of 5. It has increased from -19.00 (Mar 24) to -18.88, marking an increase of 0.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 5.63. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 5.63, marking an increase of 2.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.14. This value is below the healthy minimum of 5. It has decreased from -0.13 (Mar 24) to -0.14, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MPS Pharmaa Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -68.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -83.08% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1800.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.19
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 6.9
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 138, Roz-Ka-Meo Industrial Area, Sohna, Mewat Dist. Haryana 122103 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Peeyush Kumar Aggarwal | Managing Director |
| Mr. Ram Niwas Sharma | Non Independent Director |
| Ms. Madhu Sharma | Independent Director |
| Mr. Ajay Sharma | Independent Director |
FAQ
What is the intrinsic value of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's intrinsic value (as of 11 February 2026) is ₹2.22 which is 32.14% higher the current market price of ₹1.68, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3.21 Cr. market cap, FY2025-2026 high/low of ₹4.15/1.68, reserves of ₹-18.47 Cr, and liabilities of ₹8.99 Cr.
What is the Market Cap of MPS Pharmaa Ltd?
The Market Cap of MPS Pharmaa Ltd is 3.21 Cr..
What is the current Stock Price of MPS Pharmaa Ltd as on 11 February 2026?
The current stock price of MPS Pharmaa Ltd as on 11 February 2026 is ₹1.68.
What is the High / Low of MPS Pharmaa Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MPS Pharmaa Ltd stocks is ₹4.15/1.68.
What is the Stock P/E of MPS Pharmaa Ltd?
The Stock P/E of MPS Pharmaa Ltd is .
What is the Book Value of MPS Pharmaa Ltd?
The Book Value of MPS Pharmaa Ltd is 0.33.
What is the Dividend Yield of MPS Pharmaa Ltd?
The Dividend Yield of MPS Pharmaa Ltd is 0.00 %.
What is the ROCE of MPS Pharmaa Ltd?
The ROCE of MPS Pharmaa Ltd is 9.79 %.
What is the ROE of MPS Pharmaa Ltd?
The ROE of MPS Pharmaa Ltd is 59.0 %.
What is the Face Value of MPS Pharmaa Ltd?
The Face Value of MPS Pharmaa Ltd is 10.0.